Valeant is always adding to its arsenal of products; the most recent is a treatment for anterior uveitis that will bolster its offerings in ophthalmology.
EyeGate Pharmaceuticals announced 10 July that it has licensed US right to its lead product candidate to Valeant for an...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?